A Phase 3 interventional study of Interferon beta-1a and Ocrelizumab-matching placebo in Relapsing Multiple Sclerosis, sponsored by Hoffmann-La Roche. Completed at 165 sites in 24 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2024-03-08.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing ocrelizumab in Multiple Sclerosis — 3 open to participants now, 14 under way, 8 of them phase 3. ocrelizumab · Multiple Sclerosis.
Among the 27 studies testing ocrelizumab in Multiple Sclerosis, this one is the 4th largest by enrollment, is one of 2 that started in 2011, is one of 13 in phase 3, and was the 2nd registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.
Browse Multiple Sclerosis studies →3 of the 27 studies testing ocrelizumab in Multiple Sclerosis are open now, in 8 countries. Recruiting first, the newest first:
Genentech, Inc. · Sites in United States, Puerto Rico
Ages 18–65
Hoffmann-La Roche · Sites in Bulgaria, France, Germany and 3 more countries
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–60 · Healthy volunteers
By country, each count listing its studies:
ocrelizumab: first FDA approval 2017 (OCREVUS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2011.
This study's enrollment of 835 is above the median of 50 across 2,205 interventional studies indexed under Multiple Sclerosis.
Median enrollment 170 across the 27 interventional studies. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 27 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
35 studies in Multiple Sclerosis by Hoffmann-La Roche: 6 open now, 17 under way, 7 of them phase 3. Of 14 finished, 7 (50%) have results posted.
Among the 35 studies in Multiple Sclerosis by Hoffmann-La Roche, this one is the 5th largest by enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2011, is one of 11 in phase 3, and was the 5th registered.
Hoffmann-La Roche’s Multiple Sclerosis studies by the year they started, since 2004.
1 of the studies testing ocrelizumab in Multiple Sclerosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04466150University of California, San FranciscoImpact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies testing ocrelizumab in Multiple Sclerosis, from their registry updates:
Among Hoffmann-La Roche’s 35 in Multiple Sclerosis:
This tab as a report to print or save as PDF → With an account.
This randomized, double-blind, double-dummy, parallel-group study will evaluate the efficacy and safety of ocrelizumab in comparison with interferon beta-1a (Rebif) in participants with relapsing multiple sclerosis. Participants will be randomized to receive either ocrelizumab 600 mg or matching placebo intravenous (IV) as 300 mg infusions on Days 1 and 15 for the first dose and as a single infusion of 600 mg for all subsequent infusions every 24 weeks, with placebo injections matching interferon beta-1a SC three times per week; or interferon beta-1a 44 mcg SC injections three times per week (with placebo infusions matching ocrelizumab infusions every 24 weeks).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Interferon beta-1a 44 mcg SC injections three times per week (with placebo infusions matching ocrelizumab infusions every 24 weeks).
Drug: Interferon beta-1a · Drug: Ocrelizumab-matching placebo
Ocrelizumab 600 mg or matching placebo intravenous (IV) as 300 mg infusions on Days 1 and 15 for the first dose and as a single infusion of 600 mg for all subsequent infusions every 24 weeks, with placebo injections matching interferon beta-1a SC three times per week.
Drug: Ocrelizumab · Drug: Interferon beta-1a-matching placebo
Also known as: Rebif
Also known as: RO4964913
Annualized Relapse Rate (ARR) in Participants With Relapsing Multiple Sclerosis (MS) at 96 Weeks In Double Blind Period
ARR was protocol-defined and calculated as the total number of relapses for all participants in the treatment group divided by the total participant-years of exposure to that treatment.
Time frame: Week 96
Time to Onset of Confirmed Disability Progression (CDP) for at Least 12 Weeks During the Double-Blind Treatment Period
Disability progression was defined as an increase in the Expanded Disability Status Scale (EDSS) score of: A) \>=1.0 point from the baseline EDSS score when the baseline score was less than or equal to (\<=) 5.5 B) \>=0.5 point from the baseline EDSS score when the baseline score was \>5.5 The EDSS scale ranges from 0 (normal neurological exam) to 10 (death due to multiple sclerosis). This outcome measure was considered confirmatory only when results of both studies WA21092 and WA21093 were combined. Disability progression was considered confirmed when the increase in the EDSS was confirmed at a regularly scheduled visit at least 12 weeks after the initial documentation of neurological worsening. Participants who had initial disability progression with no confirmatory EDSS assessment and who were on treatment at time of clinical cut-off date were censored at the date of their last EDSS assessment.
Time frame: Week 104
Number of T1 Gadolinium (Gd)-Enhancing Lesions as Detected by Brain Magnetic Resonance Imaging (MRI) During the Double-Blind Treatment
The total number of T1 gadolinium-enhancing lesions for all participants in the treatment group was calculated as the sum of the individual number of lesions at Weeks 24, 48, and 96.
Time frame: Baseline up to week 96
Number of New, and/or Enlarging T2 Hyperintense Lesions as Detected by Brain Magnetic Resonance Imaging (MRI) During the Double Blind Treatment
The total number of new and/or enlarging T2 lesions for all participants in the treatment group was calculated as the sum of the individual number of lesions at Weeks 24, 48, and 96.
Time frame: Baseline up to week 96
Percentage of Participants With Confirmed Disability Improvement (CDI) for at Least 12 Weeks In Double Blind Period
Disability improvement was assessed only for the subgroup of participants with a baseline EDSS score of \>= 2.0. It was defined as a reduction in EDSS score of: A) \>=1.0 from the baseline EDSS score when the baseline score was \>=2 and \<=5.5 B) \>= 0.5 when the baseline EDSS score \> 5.5. The EDSS scale ranges from 0 (normal neurological exam) to 10 (death due to multiple sclerosis). This outcome measure was considered confirmatory only when results of both studies WA21092 and WA21093 were combined.
Time frame: Week 96
Time to Onset of Confirmed Disability Progression (CDP) for at Least 24 Weeks During the Double-Blind Treatment Period
Disability progression was defined as an increase in the Expanded Disability Status Scale (EDSS) score of: A) \>=1.0 point from the baseline EDSS score when the baseline score was less than or equal to (\<=) 5.5 B) \>=0.5 point from the baseline EDSS score when the baseline score was \>5.5 The EDSS scale ranges from 0 (normal neurological exam) to 10 (death due to multiple sclerosis). This outcome measure was considered confirmatory only when results of both studies WA21092 and WA21093 were combined. Disability progression was considered confirmed when the increase in the EDSS was confirmed at a regularly scheduled visit at least 24 weeks after the initial documentation of neurological worsening. Participants who had initial disability progression with no confirmatory EDSS assessment and who were on treatment at time of clinical cut-off date were censored at the date of their last EDSS assessment.
Time frame: Week 104
Number of T1 Hypointense Lesions During the Double-Blind Treatment
The total number of new T1-Hypo-Intense Lesions (Chronic Black Holes) for all participants in the treatment group was calculated as the sum of the individual number of new lesions at Weeks 24, 48, and 96.
Time frame: Baseline up to week 96
Change From Baseline in Multiple Sclerosis Functional Composite (MSFC) Score to Week 96 In Double Blind Period
MSFC score consists of: A) Timed 25-Foot walk; B) 9-Hole Peg Test (9-HPT); and C) Paced Auditory Serial Addition Test (PASAT-3 version). The MSFCS is based on the concept that scores for these three dimensions (arm, leg, and cognitive function) are combined to create a single score (the MSFC) that can be used to detect change over time in a group of participants with MS. Since the three primary measures differ in what they actually measure, a common composite score for the three different measures i.e., Z- score was selected for the purpose. MSFC Score = {Z arm, average + Z leg, average + Z cognitive} / 3.0. The results from each of these three tests are transformed into Z-scores and averaged to yield a composite score for each participant at each time point. A score of +1 indicates that, on average, an individual scored 1 standard deviation (SD) better than the reference population and a score of -1 indicates that an individual scored 1 SD worse than the reference population.
Time frame: Baseline, Week 96
Percent Change in Brain Volume as Detected by Brain Magnetic Resonance Imaging (MRI) From Week 24 to Week 96 In Double Blind Period
Brain volume was recorded as an absolute "normalized" value at the baseline visit then recorded at subsequent visits as a percentage change relative to the absolute value at the baseline visit. Therefore, brain volume at Week 24 was calculated as the brain volume at the baseline visit multiplied by 1 + (\[percentage change in brain volume from baseline visit to Week 24\]/100). Estimates are from analysis based on mixed-effect model of repeated measures (MMRM) using unstructured covariance matrix: Percentage Change = Brain Volume at Week 24 + Geographical Region (US vs. ROW) + Baseline EDSS (\< 4.0 vs. \>= 4.0) + Week + Treatment + Treatment\*Week (repeated values over Week) + Brain Volume at Week 24\*Week. The EDSS scale ranges from 0 (normal neurological exam) to 10 (death due to multiple sclerosis).
Time frame: From week 24 up to week 96
Change From Baseline in Short Form Health Survey-36 (SF-36) Physical Component Summary (PCS) Score at Week 96 In Double Blind Period
The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the PCS and mental composite t-score (MCS). The range for all 8 domains as well as for the composite t- scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status.
Time frame: Baseline, Week 96
Percentage of Participants Who Have No Evidence of Disease Activity (NEDA) up to Week 96 In Double Blind Period
NEDA was defined only for participants with a baseline EDSS score \>=2.0. The EDSS scale ranges from 0 (normal neurological exam) to 10 (death due to multiple sclerosis). Participants who completed the 96- week treatment period were considered as having evidence of disease activity if at least one protocol- defined relapse (PDR), a confirmed disability progression (CDP) event or at least one MRI scan showing MRI activity (defined as Gd-enhancing T1 lesions, or new or enlarging T2 lesions) was reported during the 96-week treatment period, otherwise the participant was considered as having NEDA.
Time frame: Week 96
Number of Participants With Adverse Events (AEs)
AEs included infusion related reactions (IRRs) and serious MS relapses, but excluded non-serious MS relapses. Serious Adverse Events (SAEs) included serious MS relapses and serious IRRs.
Time frame: Baseline up to Week 96
Exposure to Ocrelizumab (Area Under the Concentration - Time Curve, AUC) In Double Blind Period
AUC represents total drug exposure for one dosing interval after the 4th dose.
Time frame: Pre-infusion at Weeks 1, 24, 48, 72; and 30 minutes post-infusion at Week 72; at any time during Weeks 84 and 96
Number of Participants With Anti-Drug Antibodies (ADAs) to Ocrelizumab In Double Blind Period
Number of participants positive for anti-drug antibodies (ADAs) to ocrelizumab is the number of post- baseline evaluable participants determined to have treatment-induced ADA or treatment-enhanced ADA during the study period.
Time frame: Baseline up to Week 96
A total of 1045 participants were screened for entry into the study. Of these, 210 participants failed screening; the main reasons were failure to meet the inclusion/exclusion criteria or unacceptable laboratory values. A total of 835 participants were enrolled in the study.
| Milestone | Interferon Beta-1a + Ocrelizumab Placebo | Ocrelizumab + Interferon Beta-1a Placebo |
|---|---|---|
| Started | 418 | 417 |
| Entered ole period | 297 | 350 |
| Completed | 229 | 225 |
| Not completed | 189 | 192 |
| Withdrew: Adverse event | 40 | 42 |
| Withdrew: Death | 5 | 6 |
| Withdrew: Lack of efficacy | 22 | 10 |
| Withdrew: Lost to follow-up | 15 | 12 |
| Withdrew: Non-compliance | 3 | 7 |
| Withdrew: Non-compliance with study drug | 1 | 1 |
| Withdrew: Other | 30 | 33 |
| Withdrew: Physician decision | 11 | 16 |
| Withdrew: Pregnancy | 6 | 4 |
| Withdrew: Protocol violation | 1 | 2 |
| Withdrew: Study terminated by sponsor | 3 | 2 |
| Withdrew: Withdrawal by subject | 51 | 54 |
| Withdrew: Missing | 1 | 3 |
ARR was protocol-defined and calculated as the total number of relapses for all participants in the treatment group divided by the total participant-years of exposure to that treatment.
| relapses/participant year of treatment | Interferon Beta-1a 44 mcg SC | Ocrelizumab |
|---|---|---|
| Annualized Relapse Rate (ARR) in Participants With Relapsing Multiple Sclerosis (MS) at 96 Weeks In Double Blind Period | 0.290 (0.234 to 0.361) | 0.155 (0.121 to 0.198) |
Disability progression was defined as an increase in the Expanded Disability Status Scale (EDSS) score of: A) \>=1.0 point from the baseline EDSS score when the baseline score was less than or equal to (\<=) 5.5 B) \>=0.5 point from the baseline EDSS score when the baseline score was \>5.5 The EDSS scale ranges from 0 (normal neurological exam) to 10 (death due to multiple sclerosis). This outcome measure was considered confirmatory only when results of both studies WA21092 and WA21093 were combined. Disability progression was considered confirmed when the increase in the EDSS was confirmed at a regularly scheduled visit at least 12 weeks after the initial documentation of neurological worsening. Participants who had initial disability progression with no confirmatory EDSS assessment and who were on treatment at time of clinical cut-off date were censored at the date of their last EDSS assessment.
| weeks | Interferon Beta-1a 44 mcg SC | Ocrelizumab |
|---|---|---|
| Time to Onset of Confirmed Disability Progression (CDP) for at Least 12 Weeks During the Double-Blind Treatment Period | NA (0 to 102) | NA (0 to 104) |
The total number of T1 gadolinium-enhancing lesions for all participants in the treatment group was calculated as the sum of the individual number of lesions at Weeks 24, 48, and 96.
| lesions | Interferon Beta-1a 44 mcg SC | Ocrelizumab |
|---|---|---|
| Number of T1 Gadolinium (Gd)-Enhancing Lesions as Detected by Brain Magnetic Resonance Imaging (MRI) During the Double-Blind Treatment | 465 | 21 |
The total number of new and/or enlarging T2 lesions for all participants in the treatment group was calculated as the sum of the individual number of lesions at Weeks 24, 48, and 96.
| lesions | Interferon Beta-1a 44 mcg SC | Ocrelizumab |
|---|---|---|
| Number of New, and/or Enlarging T2 Hyperintense Lesions as Detected by Brain Magnetic Resonance Imaging (MRI) During the Double Blind Treatment | 2103 | 380 |
Disability improvement was assessed only for the subgroup of participants with a baseline EDSS score of \>= 2.0. It was defined as a reduction in EDSS score of: A) \>=1.0 from the baseline EDSS score when the baseline score was \>=2 and \<=5.5 B) \>= 0.5 when the baseline EDSS score \> 5.5. The EDSS scale ranges from 0 (normal neurological exam) to 10 (death due to multiple sclerosis). This outcome measure was considered confirmatory only when results of both studies WA21092 and WA21093 were combined.
| percentage of participants | Interferon Beta-1a 44 mcg SC | Ocrelizumab |
|---|---|---|
| Percentage of Participants With Confirmed Disability Improvement (CDI) for at Least 12 Weeks In Double Blind Period | 18.83 (14.62 to 23.65) | 21.38 (17.01 to 26.30) |
Disability progression was defined as an increase in the Expanded Disability Status Scale (EDSS) score of: A) \>=1.0 point from the baseline EDSS score when the baseline score was less than or equal to (\<=) 5.5 B) \>=0.5 point from the baseline EDSS score when the baseline score was \>5.5 The EDSS scale ranges from 0 (normal neurological exam) to 10 (death due to multiple sclerosis). This outcome measure was considered confirmatory only when results of both studies WA21092 and WA21093 were combined. Disability progression was considered confirmed when the increase in the EDSS was confirmed at a regularly scheduled visit at least 24 weeks after the initial documentation of neurological worsening. Participants who had initial disability progression with no confirmatory EDSS assessment and who were on treatment at time of clinical cut-off date were censored at the date of their last EDSS assessment.
| weeks | Interferon Beta-1a 44 mcg SC | Ocrelizumab |
|---|---|---|
| Time to Onset of Confirmed Disability Progression (CDP) for at Least 24 Weeks During the Double-Blind Treatment Period | NA (0 to 102) | NA (0 to 104) |
The total number of new T1-Hypo-Intense Lesions (Chronic Black Holes) for all participants in the treatment group was calculated as the sum of the individual number of new lesions at Weeks 24, 48, and 96.
| lesions | Interferon Beta-1a 44 mcg SC | Ocrelizumab |
|---|---|---|
| Number of T1 Hypointense Lesions During the Double-Blind Treatment | 1484 | 567 |
MSFC score consists of: A) Timed 25-Foot walk; B) 9-Hole Peg Test (9-HPT); and C) Paced Auditory Serial Addition Test (PASAT-3 version). The MSFCS is based on the concept that scores for these three dimensions (arm, leg, and cognitive function) are combined to create a single score (the MSFC) that can be used to detect change over time in a group of participants with MS. Since the three primary measures differ in what they actually measure, a common composite score for the three different measures i.e., Z- score was selected for the purpose. MSFC Score = {Z arm, average + Z leg, average + Z cognitive} / 3.0. The results from each of these three tests are transformed into Z-scores and averaged to yield a composite score for each participant at each time point. A score of +1 indicates that, on average, an individual scored 1 standard deviation (SD) better than the reference population and a score of -1 indicates that an individual scored 1 SD worse than the reference population.
| Z-score | Interferon Beta-1a 44 mcg SC | Ocrelizumab |
|---|---|---|
| Unadjusted Baseline mean (n= 342, 358) | -0.001 ± 0.033 | 0.026 ± 0.034 |
| Adjusted Week 96 mean (n= 269, 308) | 0.169 ± 0.029 | 0.276 ± 0.028 |
Brain volume was recorded as an absolute "normalized" value at the baseline visit then recorded at subsequent visits as a percentage change relative to the absolute value at the baseline visit. Therefore, brain volume at Week 24 was calculated as the brain volume at the baseline visit multiplied by 1 + (\[percentage change in brain volume from baseline visit to Week 24\]/100). Estimates are from analysis based on mixed-effect model of repeated measures (MMRM) using unstructured covariance matrix: Percentage Change = Brain Volume at Week 24 + Geographical Region (US vs. ROW) + Baseline EDSS (\< 4.0 vs. \>= 4.0) + Week + Treatment + Treatment\*Week (repeated values over Week) + Brain Volume at Week 24\*Week. The EDSS scale ranges from 0 (normal neurological exam) to 10 (death due to multiple sclerosis).
| percent change | Interferon Beta-1a 44 mcg SC | Ocrelizumab |
|---|---|---|
| Percent Change in Brain Volume as Detected by Brain Magnetic Resonance Imaging (MRI) From Week 24 to Week 96 In Double Blind Period | -0.75 ± 0.051 | -0.638 ± 0.049 |
The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the PCS and mental composite t-score (MCS). The range for all 8 domains as well as for the composite t- scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status.
| t-score | Interferon Beta-1a 44 mcg SC | Ocrelizumab |
|---|---|---|
| Unadjusted Baseline mean (n= 319, 355) | 44.552 ± 0.544 | 44.307 ± 0.541 |
| Adjusted mean change at week 96(n=276, 315) | -0.833 ± 0.472 | 0.326 ± 0.444 |
NEDA was defined only for participants with a baseline EDSS score \>=2.0. The EDSS scale ranges from 0 (normal neurological exam) to 10 (death due to multiple sclerosis). Participants who completed the 96- week treatment period were considered as having evidence of disease activity if at least one protocol- defined relapse (PDR), a confirmed disability progression (CDP) event or at least one MRI scan showing MRI activity (defined as Gd-enhancing T1 lesions, or new or enlarging T2 lesions) was reported during the 96-week treatment period, otherwise the participant was considered as having NEDA.
| percentage of participants | Interferon Beta-1a 44 mcg SC | Ocrelizumab |
|---|---|---|
| Percentage of Participants Who Have No Evidence of Disease Activity (NEDA) up to Week 96 In Double Blind Period | 24.1 (19.1 to 29.6) | 43.9 (38.1 to 49.9) |
AEs included infusion related reactions (IRRs) and serious MS relapses, but excluded non-serious MS relapses. Serious Adverse Events (SAEs) included serious MS relapses and serious IRRs.
| participants | Interferon Beta-1a + Ocrelizumab Placebo (Double Blind Period) | Ocrelizumab + Interferon Beta-1a Placebo (Double Blind Period) | Interferon Beta-1a + Placebo (Open Label Extension) | Ocrelizumab + Placebo (Open Label Extension) |
|---|---|---|---|---|
| Adverse Events | 357 | 360 | 281 | 333 |
| Serious Adverse Events | 40 | 29 | 71 | 121 |
AUC represents total drug exposure for one dosing interval after the 4th dose.
| micrograms per milliter*day | Ocrelizumab |
|---|---|
| Exposure to Ocrelizumab (Area Under the Concentration - Time Curve, AUC) In Double Blind Period | 3513 ± 955 |
Number of participants positive for anti-drug antibodies (ADAs) to ocrelizumab is the number of post- baseline evaluable participants determined to have treatment-induced ADA or treatment-enhanced ADA during the study period.
| participants | Interferon Beta-1a 44 mcg SC | Ocrelizumab |
|---|---|---|
| Positive sample at baseline (n= 407, 402) | 2 | 4 |
| Positive for ADA post-baseline (n= 403, 405) | 5 | 2 |
Collected over Baseline to approximately 588 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Interferon Beta-1a + Ocrelizumab Placebo (Double Blind) | 1/417 (0.2%) | 40/417 (9.6%) | 357/417 (85.6%) |
| Ocrelizumab + Interferon Beta-1a Placebo (Double Blind) | 1/417 (0.2%) | 29/417 (7%) | 360/417 (86.3%) |
| Interferon Beta-1a + Ocrelizumab Placebo (Double Blind) Ocrelizumab (Open Label) | 5/297 (1.7%) | 71/297 (23.9%) | 266/297 (89.6%) |
| Ocrelizumab + Interferon Beta-1a Placebo (Double Blind) Ocrelizumab (Open Label) | 6/350 (1.7%) | 121/350 (34.6%) | 317/350 (90.6%) |
| Event | Interferon Beta-1a + Ocrelizumab Placebo (Double Blind) | Ocrelizumab + Interferon Beta-1a Placebo (Double Blind) | Interferon Beta-1a + Ocrelizumab Placebo (Double Blind) Ocrelizumab (Open Label) | Ocrelizumab + Interferon Beta-1a Placebo (Double Blind) Ocrelizumab (Open Label) |
|---|---|---|---|---|
| COVID-19 PNEUMONIAInfections and infestations | 0/417 | 0/417 | 13/297 | 23/350 |
| PNEUMONIAInfections and infestations | 2/417 | 1/417 | 6/297 | 15/350 |
| COVID-19Infections and infestations | 0/417 | 0/417 | 9/297 | 13/350 |
| URINARY TRACT INFECTIONInfections and infestations | 1/417 | 0/417 | 4/297 | 3/350 |
| PYREXIAGeneral disorders | 0/417 | 0/417 | 0/297 | 3/350 |
| CHOLECYSTITISHepatobiliary disorders | 0/417 | 1/417 | 1/297 | 3/350 |
| PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders | 0/417 | 0/417 | 0/297 | 3/350 |
| APPENDICITISInfections and infestations | 0/417 | 3/417 | 0/297 | 1/350 |
| POSTOPERATIVE WOUND INFECTIONInfections and infestations | 0/417 | 0/417 | 2/297 | 0/350 |
| BREAST CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/417 | 0/417 | 2/297 | 0/350 |
| Event | Interferon Beta-1a + Ocrelizumab Placebo (Double Blind) | Ocrelizumab + Interferon Beta-1a Placebo (Double Blind) | Interferon Beta-1a + Ocrelizumab Placebo (Double Blind) Ocrelizumab (Open Label) | Ocrelizumab + Interferon Beta-1a Placebo (Double Blind) Ocrelizumab (Open Label) |
|---|---|---|---|---|
| INFUSION RELATED REACTIONInjury, poisoning and procedural complications | 50/417 | 158/417 | 97/297 | 63/350 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 53/417 | 65/417 | 86/297 | 107/350 |
| NASOPHARYNGITISInfections and infestations | 41/417 | 80/417 | 65/297 | 96/350 |
| URINARY TRACT INFECTIONInfections and infestations | 39/417 | 43/417 | 79/297 | 96/350 |
| COVID-19Infections and infestations | 0/417 | 0/417 | 66/297 | 96/350 |
| MULTIPLE SCLEROSIS RELAPSENervous system disorders | 0/417 | 0/417 | 70/297 | 82/350 |
| INFLUENZA LIKE ILLNESSGeneral disorders | 92/417 | 23/417 | 15/297 | 26/350 |
| HEADACHENervous system disorders | 71/417 | 60/417 | 49/297 | 68/350 |
| COUGHRespiratory, thoracic and mediastinal disorders | 0/417 | 0/417 | 26/297 | 58/350 |
| BRONCHITISInfections and infestations | 13/417 | 22/417 | 25/297 | 57/350 |
Intent-to-treat (ITT) population included all randomized participants in the study.
| Age, Continuous(years) | Interferon Beta-1a + Ocrelizumab Placebo (Double Blind Period) | Ocrelizumab + Interferon Beta-1a Placebo (Double Blind Period) | Total |
|---|---|---|---|
| Mean | 37.4 ± 9.0 | 37.2 ± 9.1 | 37.3 ± 9.0 |
| Sex: Female, Male(Participants) | Interferon Beta-1a + Ocrelizumab Placebo (Double Blind Period) | Ocrelizumab + Interferon Beta-1a Placebo (Double Blind Period) | Total |
|---|---|---|---|
| Female | 280 | 271 | 551 |
| Male | 138 | 146 | 284 |
Showing the first 100 of 165 sites across 24 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2011 to primary completion in May 2015, 43 months.
Results were first posted in Jul 2017, 2 years 2 months after primary completion. A results delay was requested in Oct 2016.
Of 71 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's 43 months is above that.
Counting every sponsor, half of 96 studies reached it within 42 months; a quarter within 26 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ocrelizumab